WBC
PCRX icon

Westpac Banking Corp’s Pacira BioSciences PCRX Stock Holding History

Westpac Banking Corp’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,624
Closed -$348K – 902
2017
Q1 		$348K Sell
7,624
-14
-0.2% -$605 ﹤0.01% 870
2016
Q4 		$247K Buy
7,638
+70
+0.9% +$2.34K ﹤0.01% 805
2016
Q3 		$259K Buy
7,568
+1,691
+29% +$66.3K ﹤0.01% 770
2016
Q2 		$198K Buy
5,877
+1,870
+47% +$91.9K ﹤0.01% 843
2016
Q1 		$212K Buy
4,007
+153
+4% +$8.95K ﹤0.01% 795
2015
Q4 		$296K Buy
3,854
+151
+4% +$8.55K ﹤0.01% 774
2015
Q3 		$152K Buy
3,703
+1,417
+62% +$86.8K ﹤0.01% 814
2015
Q2 		$162K Buy
2,286
+31
+1% +$2.44K ﹤0.01% 683
2015
Q1 		$200K Buy
2,255
+587
+35% +$59.6K ﹤0.01% 890
2014
Q4 		$148K Buy
1,668
+1,042
+166% +$98.6K ﹤0.01% 909
2014
Q3 		$60.7K Buy
+626
New +$60.9K ﹤0.01% 923

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Westpac Banking Corp's PCRX Position: Q2 2017 in Review

Westpac Banking Corp sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 7,624 shares — an estimated $348K sold.

Westpac Banking Corp first reported a position in PCRX in Q3 2014 and held it in 11 quarters. The position peaked at $348K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Westpac Banking Corp reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Westpac Banking Corp sold 7,624 Pacira BioSciences shares in Q2 2017, an estimated $348K.
  • Westpac Banking Corp first reported a position in Pacira BioSciences in Q3 2014 and held it in 11 quarters.
  • Westpac Banking Corp's Pacira BioSciences position peaked at $348K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Westpac Banking Corp's 13F filing for Q2 2017, filed 9 Aug 2017.